| Members |
targetComponentId |
| CDC group DF-2 |
Capnocytophaga canimorsus |
| CDE genotype |
CDE haplotype (finding) |
| CDe genotype |
CDe haplotype (finding) |
| CTV3 ROOT |
SNOMED CT Concept |
| kål, livsmedel |
Cabbage (substance) |
| Cabergoline [parkinsons] |
Product containing cabergoline (medicinal product) |
| Caffeine and sodium benzoate injection |
Product containing caffeine and sodium benzoate (medicinal product) |
| koffeininnehållande substans, icke läkemedel |
Caffeine |
| café-au-lait-fläckar och ringkromosom 11 |
Ring chromosome 11 syndrome |
| kalcipotrien 0,005 %/betametason 0,064 %, suspension för lokalt bruk |
Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 milliliter and calcipotriol 50 microgram/1 milliliter conventional release cutaneous lotion (clinical drug) |
| kalcitonin från lax 100 enheter/ml, injektionsvätska, lösning, flaska 1 ml |
Product containing precisely salmon calcitonin 100 unit/1 milliliter conventional release solution for injection (clinical drug) |
| laxkalcitonin 200 IE/ml, sprej |
Product containing precisely salmon calcitonin 200 unit/1 actuation conventional release nasal spray (clinical drug) |
| Calcitonin, salmon 200unt/mL injection |
Salmon calcitonin 200 unit/mL solution for injection |
| kalcitonin från lax 200 enheter/ml, injektionsvätska, lösning, flaska 2 ml |
Salmon calcitonin 200 unit/mL solution for injection |
| Calcium analyte |
Calcium |
| kalciumbaserat antacidum |
Calcium compound |
| kalciumkarbonat 1,25 g + kolekalciferol 11 mikrogram, dospåse med granulat |
Calcium carbonate 6.25 mg/mL and colecalciferol 2.2 unit/mL oral solution |
| kalciumklorid 10 %, injektionsvätska, lösning, förfylld spruta 10 ml |
Product containing precisely calcium chloride 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| kalciumhydroxiapatit, mikrosfärsuspension i vattenbaserad bärare, förfylld spruta 0,3 ml |
Hydroxyapatite only product in parenteral dose form |
| kalciumhydroxiapatit, mikrosfärsuspension i vattenbaserad bärare, förfylld spruta 1,3 ml |
Hydroxyapatite only product in parenteral dose form |
| kalciumfosfat 3 100 mg + cholekalciferol 20 mikrogram per dospåse, pulver till oral suspension |
Calcium phosphate and colecalciferol only product |
| Calculus - composition |
Finding of stone composition (finding) |
| kalfaktant, intratraekal suspension, flaska 6 ml |
Product containing only calfactant (medicinal product) |
| Calicivirus group |
Family Caliciviridae (organism) |
| Calliphora erythrocephala |
Calliphora vicina |
| Callitrogae |
Genus Cochliomyia (organism) |
| Caloric intake, function (observable entity) |
Energy intake (observable entity) |
| Caloscypha fulgens |
Caloscypha fulgens (organism) |
| Calymmatobacterium granulomatis |
Klebsiella granulomatis (organism) |
| Campylobacter cinaedi |
Helicobacter cinaedi |
| Campylobacter fennelliae |
Helicobacter fennelliae |
| Campylobacter laridis |
Campylobacter lari |
| Campylobacter laridis rRNA |
Campylobacter lari rRNA |
| Campylobacter laridis rRNA assay |
Campylobacter lari rRNA assay |
| Campylobacter nitrofigilis |
Arcobacter nitrofigilis (organism) |
| kanakinumab 150 mg, pulver till injektionsvätska, lösning |
Canakinumab only product |
| cancervårdplan |
Cancer care plan |
| Cancer care plan |
Cancer care plan |
| Cancer care plan |
Cancer care plan |
| genomgång av cancerbehandling |
Cancer care review (procedure) |
| utförd screening för livmoderhalscancer |
Screening for malignant neoplasm of cervix done (situation) |
| Candida famata |
Debaryomyces hansenii |
| Candida famata |
Debaryomyces hansenii |
| Candida humicola |
Vanrija humicola (organism) |
| Candida krusei var. vanlaeriana |
Pichia membranifaciens (organism) |
| Candida lipolytica |
Yarrowia lipolytica |
| Candida pseudotropicalis |
Kluyveromyces marxianus |
| Candidiasis of other specified sites |
Candidiasis |
| Candidiasis of other urogenital sites |
Candidiasis of urogenital site |
| Canine cortical hyperostosis |
Disorder of bone (disorder) |
| Canis familiaris |
Canis lupus subspecies familiaris (organism) |
| Canis rufus |
Canis lupus subspecies rufus (organism) |
| Cannabinoid |
Cannabis (substance) |
| Cannabinoid - non-pharmaceutical |
Cannabis (substance) |
| kannabisgräs, icke läkemedel |
Cannabis (substance) |
| kannabisblad, icke läkemedel |
Cannabis leaf (substance) |
| kannabisolja, icke läkemedel |
Cannabis oil (substance) |
| kannabisharts, icke läkemedel |
Cannabis resin (substance) |
| Cannulation - action |
Insertion - action (qualifier value) |
| kapillära hemangiom, kategori |
Capillary hemangioma |
| Capnocytophaga canimorsus |
Capnocytophaga canimorsus |
| Caprine adenovirus |
Goat adenovirus (organism) |
| kapsaicin 179 mg/timme, depåplåster |
Product containing precisely capsaicin 179 milligram/1 each conventional release cutaneous patch (clinical drug) |
| kapsel i distal interfalangealled i stortå, struktur |
Structure of capsule of interphalangeal joint of great toe |
| kaptoprilallergi |
Non-allergic hypersensitivity to captopril (finding) |
| karbakol 1 %, ögondroppar |
Product containing precisely carbachol 10 milligram/1 milliliter conventional release eye solution (clinical drug) |
| karbakol 1,5 %, ögondroppar |
Carbachol 15 mg/mL eye solution |
| Carbachol 1.5% solution |
Carbachol 15 mg/mL eye solution |
| karbakol 250 mikrogram/ml, injektionsvätska, lösning, ampull 1 ml |
Product containing precisely carbachol 250 microgram/1 milliliter conventional release solution for injection (clinical drug) |
| karbamazepin 100 mg, kapsel med modifierad frisättning |
Carbamazepine only product in oral dose form |
| karbamazepin 100 mg, tablett med modifierad frisättning |
Carbamazepine only product in oral dose form |
| karbamazepin 100 mg, depåkapsel |
Carbamazepine only product in oral dose form |
| karbamazepin 100 mg, depåtablett |
Carbamazepine only product in oral dose form |
| karbamazepin 200 mg, kapsel med modifierad frisättning |
Carbamazepine only product in oral dose form |
| karbamazepin 200 mg, depåkapsel |
Carbamazepine only product in oral dose form |
| karbamazepin 300 mg, kapsel med modifierad frisättning |
Carbamazepine only product in oral dose form |
| karbamazepin 300 mg, depåkapsel |
Carbamazepine only product in oral dose form |
| karbenoxolonnatrium 1 %, granulat till munsköljvätska |
Carbenoxolone only product |
| karbenoxolonnatrium 2 %, oral gel |
Product containing precisely carbenoxolone 20 milligram/1 gram conventional release oral gel (clinical drug) |
| karbidopa 25 mg + levodopa 100 mg, tablett med modifierad frisättning |
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet |
| karbidopa 50 mg + levodopa 200 mg, tablett med modifierad frisättning |
Product containing precisely carbidopa 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet (clinical drug) |
| karbidopa 10 mg + levodopa 100 mg, munsönderfallande tablett |
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
| karbidopa 18,75 mg + levodopa 75 mg + entakapon 200 mg, tablett |
Carbidopa anhydrous (as carbidopa) 18.75 mg and entacapone 200 mg and levodopa 75 mg oral tablet |
| Carbidopa 25mg |
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram/1 each conventional release oral tablet (clinical drug) |
| karbidopa 25 mg + levodopa 100 mg, munsönderfallande tablett |
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
| karbidopa 25 mg + levodopa 250 mg, munsönderfallande tablett |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 250 mg orodispersible tablet |
| karbidopa 31,25 mg + levodopa 125 mg + entakapon 200 mg, tablett |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet |
| karbinoxaminmaleat 1 mg/ml + dextrometorfanhydrobromid 4 mg/ml + pseudoefedrinhydroklorid 15 mg/ml, droppar |
Product containing precisely carbinoxamine maleate 1 milligram/1 milliliter and dextromethorphan hydrobromide 4 milligram/1 milliliter and pseudoephedrine hydrochloride 15 milligram/1 milliliter conventional release oral solution (clinical drug) |
| karbinoxaminmaleat 4 mg/5 ml + dextrometorfanhydrobromid 12,5 mg/5 ml + pseudoefedrinhydroklorid 60 mg/5 ml, sirap |
Product containing precisely carbinoxamine maleate 800 microgram/1 milliliter and dextromethorphan hydrobromide 2.5 milligram/1 milliliter and pseudoephedrine hydrochloride 12 milligram/1 milliliter conventional release oral solution (clinical drug) |
| karbinoxaminmaleat 4 mg/5 ml + dextrometorfanhydrobromid 15 mg/5 ml + pseudoefedrinhydroklorid 60 mg/5 ml, sirap |
Product containing precisely carbinoxamine maleate 800 microgram/1 milliliter and dextromethorphan hydrobromide 3 milligram/1 milliliter and pseudoephedrine hydrochloride 12 milligram/1 milliliter conventional release oral solution (clinical drug) |
| karbinoxaminmaleat 1 mg/ml+ pseudoefedrinhydroklorid 15 mg/ml, droppar |
Carbinoxamine maleate 1 mg/mL and pseudoephedrine hydrochloride 15 mg/mL oral solution |
| karbinoxaminmaleat + pseudoefedrinhydroklorid 8 mg/120 mg, tablett med modifierad frisättning |
Product containing only carbinoxamine and pseudoephedrine in oral dose form (medicinal product form) |
| karbinoxaminmaleat 8 mg + pseudoefedrinhydroklorid 120 mg, depåtablett |
Product containing only carbinoxamine and pseudoephedrine in oral dose form (medicinal product form) |
| Carbohydrate agent |
Carbohydrate |
| karbolfuksin |
Carbol-fuchsin (substance) |
| Carbon-carbon lyase |
Carbon-carbon lyase |
| Carbon-halide lyase |
Carbon-halide lyase |
| Carbon-nitrogen lyase |
Carbon-nitrogen lyase |
| Carbon-oxygen lyase |
Carbon-oxygen lyase |
| Carbon-sulfur lyase |
Carbon-sulfur lyase (substance) |
| Carboxy-lyase |
Decarboxylase |